News

European patient shows signs of PML

The pharmaceutical sponsor of Tecfidera (BG-12), Biogen Idec, has this week reported one case of Progressive Multifocal Leukoencephalopathy (PML) in an individual currently being treated with Tecfidera in Europe.

Over 100 000 people around the world have been treated with Tecfidera, and this is the first reported case of PML in someone receiving this treatment. It is not yet clear the treatment history of this individual, and the extent to which Tecfidera has contributed.

Progressive multifocal leukoencephalopathy (PML) is a rare and potentially fatal viral brain infection characterised by progressive damage to the white matter of the brain. It is caused by the JC virus (JCV), which is present in about half of the general population, but only manifests in people whose immune system has been suppressed, including those on immunosuppressive medication. PML in people with MS is known to be a relatively rare safety risk of natalizumab treatment, with most cases of PML occurring after more than two years of natalizumab treatment.

This event should not be a cause for alarm in people currently taking this medication, and it is very important that people should not make any changes to their current medication regimen without first seeking medical advice. If you have any concerns about your current treatment plan, please speak to your neurologist.

tysabri-website-image

Flexible MS Care: New form of Tysabri® now available on the PBS

The Federal Government has announced the listing of new form...
Rohan Greenland The May 50K

From our CEO

Without doubt, 2024 is going to be a busy and...

Want us to keep you in the loop? Subscribe today!

  • Enter your details

Read More

Newsletter subscription

  • Enter your details

European patient shows signs of PML